Varian, Proxima set up new brachytherapy fee scheme
This article was originally published in Clinica
More US patients with early stage breast cancer can now have access to accelerated partial breast brachytherapy, following a pact between Varian Medical Systems and Proxima Therapeutics that will enable hospitals to acquire high-dose-rate (HDR) radiotherapy equipment at more affordable rates.
You may also be interested in...ď»ż
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilicoâ€™s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.